Cell cycle regulatory proteins p27kip1, cyclins D1 and E and proliferative activity in oncocytic (Hürthle cell) lesions of the thyroid

Endocrine Pathology

Volumn 11, Issue 4, 2000, Pages 331-340

  Maynes, Lincoln J ^a   Hutzler, Michael J ^a   Patwardhan, Nilima A ^a   Wang, Songtao ^a   Khan, Ashraf ^a  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Cyclin D1; Cyclin E; Cyclins; H rthle cell tumors; H rthle cells; Ki67; Oncocytic cells; Oncocytic tumors; p27

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN E; CYCLINE; KI 67 ANTIGEN; PROTEIN P27;

ARTICLE; CANCER GROWTH; CELL CYCLE; CELL PROLIFERATION; COMPLEX FORMATION; ENZYME ACTIVATION; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NODULAR GOITER; ONCOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; THYROID PARAFOLLICULAR CELL;

EID: 0034442127     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1385/EP:11:4:331     Document Type: Article

References (46)

1. 1. Rosen IB, Luk S, Katz I. Hürthle cell tumor behavior: dilemma and resolution. Surgery 98:777-783, 1985.
2. 2. Gosain, AK, Clark OH. Hürthle cell neoplasms. Malignant potential. Arch Surg 119:515-519, 1984.
3. 3. Caplan RH, Abellera RM, Kisken WA. Hürthle cell tumors of the thyroid gland: A clinicopathologic review and long-terms follow-up. JAMA 251:3114-3117, 1984.
4. 4. Flint A, Lloyd RV. Hürthle-cell neoplasms of the thyroid gland. Pathol Annu 25:37-52, 1990.
5. 5. Chen H, Nicol TL, Zeiger MA, et al. Hürthle cell neoplasms of the thyroid: are there factors predictive of malignancy? Ann Surg 227:542-546, 1998.
6. 6. Bondeson L, Azavedo E, Bondeson AG, Caspersson T, Ljungberg O. Nuclear DNA content and behavior of oxyphil thyroid tumors. Cancer 58:672-675, 1986.
7. 7. Flint A, Davenport RD, Lloyd RV, Beckwith AL, Thompson NW. Cytophotometric measurements of Hürthle cell tumors of the thyroid gland. Correlation with pathologic features and clinical behavior. Cancer 61:110-113, 1988.
8. 8. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 68:67-108, 1996.
9. 9. Dirks PB, Rutka JT. Current concepts in neuro-oncology: the cell cycle - a review. Neurosurgery 40(5):1000-1015, 1997.
10. 10. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149-1163, 1995.
11. 11. Kawamata N, Morosetti R, Miller CW, et al. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/kip1 in human malignancies. Cancer Res 55:2266-2269, 1995.
12. 12. Pietenpol JA, Bohlander SK, Sato Y, et al. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 55:1206-1210, 1995.
13. 13. Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW, Koeffler HP. p27/kip1 mutation found in breast cancer. Cancer Res 56:2400-2404, 1996.
14. 14. Kiyokawa H, Kineman RD, Manova-Todovora KO, et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27 (Kip1). Cell 85:721-732, 1996.
15. 15. Nakayama K, Ishida N, Shirane M, et al. Mice lacking p27 (Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85:707-720, 1996.
16. 16. Fero ML, Rivkin M, Tasch M, et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27 (Kip1)-deficient mice. Cell 85:733-744, 1996.
17. 17. Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature 372:570-573, 1994.
18. Kip1 accumulation during the cell cycle. Science 271:1861-1864, 1996.
19. 19. Fredersdorf S, Burns J, Milne AM, et al. High-level expression of p27/kip1 and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27/kip1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94:6380-6385, 1997.
20. 20. Loda M, Cukor B, Tam SW, et al. Increased proteasome-dependent degradation of the cyclin-dependent inhibitor p27 in aggressive colorectal carcinomas. Nat Med 3:152-154, 1997.
21. 21. Guo Y, Sklar GN, Borkowski A, Kyprianou N. Loss of the cyclin-dependent inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res 3:2269-2274, 1997.
22. 22. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non small cell lung cancer. Cancer Res 57:3381-3385, 1997.
23. 23. Lloyd RV, Jin L, Qian X, Kulig E. Aberrant p27kip1 expression in endocrine and other tumors. Am J Pathol 150:401-407, 1997.
24. 24. Qian X, Jin L, Grande JP, Lloyd RV. Transforming growth factor-beta and p27 expression in pituitary cells. Endocrinology 137: 3051-3060, 1996.
25. 25. Erickson LA, Jin L, Wollan PC, Thompson GB, van Heerden J, Lloyd RV. Expression of p27kip1 and Ki-67 in benign and malignant thyroid tumors. Mod Pathol 11:169-174, 1998.
26. 26. Resnick MB, Schacter P, Finkelstein Y, Kellner Y, Cohen O. Immunohistochemical analysis of p27/kip1 expression in thyroid carcinoma. Mod Pathol 11:735-739, 1998.
27. 27. Wang S, Wuu J, Savas L, Patwardhan N, Khan A. The role of cell cycle regulatory proteins, cyclin D1 cyclin E, and p27 in thyroid carcinogenesis. Human Pathol 29:1304-1309, 1998.
28. 28. Donnellan R, Chetty R. Cyclin D1 and human neoplasia. J Clin Pathol: Mol Pathol 51:1-7, 1998.
29. 29. Zou M, Shi Y, Farid NR, Al-Sedairy ST. Inverse association between cyclin D1 overexpression and retinoblastoma gene mutation in thyroid carcinomas. Endocrine 8:61-64, 1998.
30. 30. Lazzereschi D, Sambuco L, Carnovale Scalzo CC, et al. Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinoma, Inct J Cancer 76:806-811, 1998.
31. 31. Erickson LA, Jin L, Goellner JR, et al. Pathologic features, proliferative activity and cyclin D1 expression in Hurthle cell neoplasms of the thyroid. Mod Pathol 13:186-192, 2000.
32. 32. Porter PL, Malone KE, Heagerry PJ, et al. Expression of cell-cycle regulators p2/Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3:222-225, 1997.
33. 33. Gerdes J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. Sem Cancer Biol 1:199-206, 1990.
34. 34. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathology 17:489-503, 1990.
35. 35. Tallini G, Garcia-Rostan G, Herrero A, et al. Downregulation of p27KIP1 and Ki67/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories. Am J Surg Pathol 23:678-685, 1999.
36. 36. Sgambato A, Zhang YJ, Arber N, et al. Deregulated expression of p27(Kip1) in human breast cancers. Clin Cancer Res 3:1879-1887, 1997.
37. 37. Vrhovac R, Delmer A, Tang R, Marie JP, Zittoun R, Ajchenbaum-Cymbalista F. Prognostic significance of the cell cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. Blood 91:4694-4700, 1998.
38. 38. Sanchez-Beato M, Camacho FI, Martinez-Montero JC, et al. Anomalous high p27/KIP1 expression in a subset of aggressive B-Cell lymphomas is associated with cyclin D3 overexpression. P27/KIP1-cyclin D3 colocalization in tumor cells. Blood 94:765-772, 1999.
39. 39. Baldassarre G, Belletti B, Bruni B, et al. Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. J Clin Invest 104(7): 865-874, 1999.
40. 40. Sherr CJ. D-type cyclins. Trends Biochem Sci 20:187-190, 1995.
41. 41. Resnitzky D, Gossen M, Bujard H, Reed SI. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 14:1669-1679, 1994.
42. 42. Ewen ME, Sluss HK, Sherr CJ, Matsushime H, Kato J, Livingston DM. Functional interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell 73:487-497, 1993.
43. 43. Hinds PW, Mittnacht S, Dulic V, Arnold A, Reed SI, Weinberg RA. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell 70:993-1006, 1992.
44. 44. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 15:2612-2624, 1995.
45. 45. Wimmel A, Lucibello FC, Sewing A, Adolph S, Müller R. Inducible acceleration of G1 progression through tetracyclin-regulated expression of human cyclin E. Oncogene 9:995-997, 1994.
46. 46. Wang S, Lloyd RV, Hutzler MJ, Safran MS, Patwardhan NA, Khan A. The role of cell cycle regulatory protein cyclin D1 in the progression of thyroid cancer. Mod Pathol 13:882-887, 2000.